サプリメント4.PDF
|
|
|
- よりお こけい
- 7 years ago
- Views:
Transcription
1 Vol.13,No, Oct.200Vol.13 No. ACE mmHg ACE ACE ACE
2 Vol.13,No.4, L- L- EPA DHA B 2002 a. CSPHP A D E K b. TG DAG DA EPA/DHA EPA DHA n-3 n- EPA DHA n- EPA DHA
3 Vol.13,No, n-6 n- n- n-3 CT CCM CPP K2-7 CCMCPP D3 3
4 Vol.13,No.4, CPP-ACP C 1, E Q10
5 Vol.13,No, n-6 n-3 n-3 n-6 EPA
6 Vol.13,No.4, ED ED 1530mg 1530mg 50200g 6070g L- ED 80% 400mg/ ED L- ED 700mg 1500mg/ DHEA ED ED ED L- QOL
7
8
9 Vol.13,No, No.1 K ACE Ca No.2 H2 A 2 K No.3 L
10 Vol.13,No.4, No Q B1 134 B B D 135 E 136 K CSPHP 138
11 Vol.13,No,2004 c) (6) 36:6.176, c) (7) 36:7.242, c) (8) 36:8.189,2000 A c) (9) 36:9.162, c) (10) 36:10.278, c) (11) 36:11.166, c) (12) 36:12.155, d)(1) 37:1.200, d) (2) 2 37:2.131, a) e) 35:11.168, :3.229, b) f) 35:11.168, :4.172, c) g) (1) 36:1.178, :5.135, c) h) (2) 36:2.192, :6.209, c) I) (3) 36:3.189, :7.190, c) a) (4) 36:4.142, :8.177, c) b) (5) 36:5.139, :9.186,
12 Vol.13,No.4, c) 37:10.278, d) 37:11.171, a) A 37:12.138, b) 38:1.174, c) D 38:2.150, c) (13) 38:3.135, c) (14) 38:4.155, c) (15) 38:5.164, d) (1) 38:6.117, d) (2) 38:7.154, a) (3) 38:8.126, a) (4) 38:9.129, a) (5) 38:10.270, b) 38:11.146, c) B6 38:12.182, d) 39:1.192, a) 39:2.153, ) 422. b) 39:3.125, e) 39:4.139, f) 39:5.168, c) 39:6.134, d) 39:7.212, e) 39:8.154, f) (1) 39:9.138, f) (2) 39:10.135, f) (3) 39:11.140, f) (4) 39:12.217, j) 40:1.131, :9.836, :9.841, :9.846, :9.850,
13 Vol.13,No, :9.856, ) 19:9.861, :4.815, ) 19:9.864,2000 6:8.22, ) 6 19:9.868, :7.119, ) 7 19:9.874, :8.121, ) 8 19:9.878, :9.121, ) 9 19:9.882, :12.117, :9.886, :9.890, OTC 19:9.892, ) 21:7.711, ) 21:8.859, ) 21:8.915, ) (1) 21: , ) (2) 21: , ) (3) 21: , ) 95) 55:5.23,2004 (4) 21: ) 22:2.146, ) 22:5.480, ) 22:6.600, ) Warfarin 116
14 Vol.13,No.4, :6.538,2004 TEL(096) FAX(096)
Vol.9No.22012
6 21 2 21 8 7 118 Vol.9No.22012 6 2 3 1 10 10 1 13 1 13 1320 1956 1961 1977 21 8 1979 1981 1982 2011 2003 20062011 Vol.9No.22012 119 1 23 8 21 1 1 24 20 22 18 8 120 Vol.9No.22012 2 9 1953 2 1979 2 2 1982
サンプル一覧表.PDF
: 1 30 1 : 1 30 : 8662 60 : 4810 30 1 : 19383 90 : 8872 : 6279 : 7098 180 120 90 : 6405 120 : 7234 :3276 60 280 : 8053 180 : 5512 180 : 4368 100 :4462 120 : 4725 120 : 8851 180 : 3024 180 : 3286 150 :
2
5 15.8% 17.1% 13.7% 15 1 34.0%3 1 3 25.7 4 1 76.5 3.3 2 23 3225 36 72.0 13.3 1 26 38 ( 77.8 87.8 69.5 2010 3 20 60 7 20 2 3 1 2 ( 77.8 87.8 69.5 2010 87.9 66.5 3 20 83.030 92.240 93.6 50 91.660 6065 72.9
取扱説明書
ED-601 ED-501 ED-401 2 3 4 23 14 5 6 18 10 7 1 2 6 3 4 8 9 16 16 16 12 1 2 18 10 2 1 5 12 11 1 2 1 2 12 1 2 13 16 14 3 2 4 1 1 2 16 3 4 18 15 1 2 16 2 3 1 1 2 3 18 17 18 22 19 D A C 20 A B 22 B C D 22
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
橡サプリメント.PDF
Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004
2
() () 980-8578 Tel: 022-795-6092 Fax: 022-795-6096 email: 1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 17 46 47 4.1.1
![かんたん操作ガイド[arrows M02]](/thumbs/39/20071242.jpg "かんたん操作ガイド[arrows M02]")
![かんたん操作ガイド[arrows RM02]](/thumbs/39/20475147.jpg "かんたん操作ガイド[arrows RM02]")
![かんたん操作ガイド[arrows M03]](/thumbs/42/22941141.jpg "かんたん操作ガイド[arrows M03]")
甲状腺疾患２.PDF
Vol.14,No1,2005 74 Jan.2005 Vol.14 No.1 Vol.14,No.1,2005 75 Vol.14,No1,2005 76 37.5 TSH TSH TRAb TRAb TSH Vol.14,No.1,2005 77 Vol.14,No1,2005 78 Vol.14,No.1,2005 79 T4 T3 16) S Vol.14,No1,2005 80 1 1.
arakidonsan.rtf
DHA (ARA) ARA DHA 50 DHA 20 DHA( ) γ 300 mg 170 mg 150 mg 78 mg 57 mg 3,200 mg 2,300 mg 1,700 mg 1,700 mg 1,700 mg β- E FAO DHA( ARA) DHA 2ARA 1 DHA 70mg 100g 35mg 100g 6 6 63 EPA DHA 63 6 EHA DHA 50 WEB
2015taisetumatome.rtf
B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4
木材利用における林野庁施策の動向１
10 1931 10 1050 H21 2,900 45.9% (14%) 253 4.0% 6,321m 3 (100%) 816 12.9% (21%) m 3 2,351 37.2% (41%) 8130 598 1,024m 3 8248% 198m 3 58 7% 1,758m 3 55% 48%+7%=55% 22 519 26 10 4 1 3 Vol53No.4,1998
EL-G37
EL-G37 A A A A A A A A A A A A A A GT F543210A CE CA 4 00. 00 23.80 2 015.6250 77.14286 96. 91. 102. 25. 9. 1 700. 2 720. 2.5 7. 20. 25. 220. 400. 4 096. 4.685 0.084 M 125. M 28. M 85.
コンタクト.PDF
Vol.12,No.4,2003 Sep.2003 Vol.12 No.4 CL CL HCL BAK CL 5 1/10 CL 5 CL 80% CL CL 6 2 CL CL 3 67 Vol.10,No1,2001 ph 7.5 3 2 9mm 90% 7 2 68 1 12ml 3 3 3 Vol.10,No.1,2001 69 IgA 1 0.16 2L CL Vol.10,No1,2001
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
AJISAI10-1.PDF
Vol.10,No.1,2001 Jan.2001 Vol.10 No.1 *1 50 10 30 DDT 1980 200 Sarcoptes Scabiei var 0.330.35mm 0.25 Hominis 0.35mm 2/3 1mm 4 1 Vol.10,No1,2001 4 1040 2mm 23 20%KOH 1 13 34 6 2 1417 8 4 1014 45 1025 10
嚥下障害.PDF
Vol.16,No2,007 21 Oct.200Vol.16 No.2 OD oral Disintegrant Vol.16,No2,2007 22 3 Vol.16,No.1,2007 3 Vol.16,No2,2007 4 Vol.16,No.2,2007 5 Vol.16,No2,2007 6 Vol.16,No.2,2007 7 OD Orally Disintegrating D
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
Vol.35/No.405 4A pril 2011 Vol.35/No.405 4 April 2011 C O N T E N T S 13 2 04 4 48 6 8 Monthly Digest 10 11 12 13 INFORMATION 14 2010 2011234vol.35 No.4052341 540-0011 2-1-10 Tel.0669467065 Fax.0669460004
ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
BAANs理論に基づく保健指導プログラム暫定版
WHO 4 5 10% L- -3 RNA L - 1960-3 RNA mrna Bio Activating Advanced Nutrients BAANs BAANs BAANs BAANs L- (NO) -3 EPA, DHA) RNA RNA DNA TNF- PAI-1 ( ) BAANs 40 50% 20% 1Kg 7,000Kcal 50Kcal 11 50Kcal
RP. 1 15 5 0.5g/ 1 1 1 2 1 2 28 5mg/ 1 1 1 3 20 105 S-1 4 2 2 3 3 day15 15 S-115 S-1 S-1 0.12 0.22 0.12 106 2 107 3 65S-13day15 S-1 S-1 108 109 1 1 S-1 33-1 S-1 110 S-1 3day15 1 4 2 116 -1 5 1-2 2-3 day3
資料３ 危害や迷惑問題等への対応状況
1 2 3 4 16 12 9 1 5 6 7 8 9 10 11 H16 12 91 10 60 30 13 13 16 12 15 16 14 15 16 (1) (2) (3) 17 18 19 20 () 21 HP http://www.ktr.mlit.go.jp/sinrin/dogrun.htm 22 23 14 5 24 25 11 26 Vol.57No.12004 Vol.56No.122003
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
1
6 1 1999 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68
341-4改
ADEK -COOH 2 22 a) IUPAC 4 6 18 b 1 1 c t 9 9 C 4 CH 3 (CH 2 ) 2 COOH 40 6 8 10 12 14 16 18 20 22 CH 3 (CH 2 ) 4 COOH CH 3 (CH 2 ) 6 COOH CH 3 (CH 2 ) 8 COOH CH 3 (CH 2 ) 10 COOH CH 3 (CH 2 ) 12 COOH CH
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
untitled
...1... 3 1... 3 2... 4 3... 4 4... 5...... 6 1... 6 2... 7 3... 8 4... 9 5... 10... 12 1... 12 2... 13 3... 14 4... 16...... 19 1... 19 2... 20 3... 22 4... 24...... 25... 26 1... 26 2... 26 3... 26......
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
untitled
Vol.36No.1 C O N T E N T S Sundkrogskaj 20, 2100 København ø, Denmark Website: http://www.frinet.dk/index.aspx Email: fri@frinet.dk Phone: 4535253737, Fax : 4535253738 AJCE
14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115
2014 6 107 114 総 説 2014 7 25 2014 8 1 2014 1 20 OTC 107 2014 6 115 123 総 説 I -VG, 2014 7 24 2014 8 15 -VG, -VG 115 2014 6 124 132 原 著 1, 2, 3 4, 5 6 7 8 9 10 3 11 12 1 2 3 4 5 6 7 8 9 10 11 12 2014 3 24
untitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
190 87 28 1 212 77 1777 77 219 1 171 28 201 1 1 16 102 17 10 1 16 99 1 1 1 1 960 1 1 1 1 1 2 168 1 12 2 18 100 2 1 6 1 61 7 16 18 20 2 961 2 11 6 2 6 6 0 17 86 1 2 16 1 1 9 2 1 1 1 1 1 1 0 2 17 16 6 1
本文 ５３集／９ 駒田 白
Green-Soybean Preference of Gife City Elementary School Students and Practical Use of Its Akiko KOMADA Key words Green-Soybean. Elementary School Students. Practical Use. B B B B g g gg g gg g g g B B
PSCHG001.PS
com plex regional pain syndrom ecrps TPP TPP TPP TPP TEL FA X B M GUS M M CHDF H g Virtual reality PC m onster parents mislead Midnight w alking NHK Skype NHK BS DJ DJ DVD DVD DVD TV BS H H H
粉砕No.2.doc
Vol.10,No,2001 50 Ma.2001 Vol.10 No. 2 Vol.10,No.,2001 49 Spansules ph Spansules L- ph ph Alza Oros Vol.10,No,2001 50 Vol.10,No.,2001 51 [] 1:2.89,1995 [] 35:3.167,1993 [] 35:4.105,1993
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
, ,279 w
No.482 DEC. 200315 14 1754,406 100.0 2160,279 w 100 90 80 70 60 50 40 30 20 10 28.9 23.8 25.0 19.3 30.4 25.0 29.5 80.7 75.0 75.0 70.5 71.1 69.6 76.2 7 8 9 10 11 12 13 23.2 76.8 14 14 1751,189 100.0 2156,574
平成１４年第８回白根町議会臨時会（１日目）
EPA EPA 10 4 9 10 4 9 10 4 9 10 4 9 NONO () NONO 9 EPA EPA WTO WTO CATV () CATV ( ) () () (2 ) () () CATV A () ()() () () () () 4 2 1 H19,7 1 5 1 H19,4 2 1 1 1 1 1 5 () CATV CATV CATV CATV
BMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
untitled
CA 04 1,360 100.8 0.1 83 34,176 7.61 0.40 51,532 1.3 322,736 5.9 05 1,369 100.0 0.8 80 57,269 7.86 0.43 55,001 6.7 311,107 3.6 06 1,370 99.8 0.2 83 48,250 7.73 0.46 56,369 2.5 319,129 2.6 06/ 1-3 99.4
32 TEL: 0959-52-3000 FAX: 0959-52-4467 Email: nkh@orange.ocn.ne.jp URL: http://www.kamigoto-hospital.jp/ 1 73 MRI IT IVR PTCA 74 MC CT) NECMega-Ork 75 Web HTLV-IATL 2 ICU Holter MD-C T MRIX DSAFCR 3 4
62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -
![62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -](/thumbs/41/22310901.jpg "62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC -")
1 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] g/dl A 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - 62 [ ] [ ] [ ] [ ] [ ] [ ] / / [ ] 1T OTC - [ ] Point ~ 62 [ ] [ ] [ ] [ ] [ ] [ ] / /
商学５７‐５／１．山村
217 1982 1998 2002 14 7 7 250 3 2 2004 16 2004 a 90 218 1 1 1948 23 25 19 2004 47 3 13 2 14 1969 2 25 25 20 21.1 70 34.5 40 219 50 25 2004 1kg1 l 1,000 mg1 g 250 mg 1mg 1mg 1 mg 19 1911 44 2005 25 50 1498
近畿中国四国農業研究センター研究報告 第７号
230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15
-1-19 753-0214 TEL 083-927-7031083-927-7029 FAX 083-927-0214 e-mail a17201@pref.yamaguchi.lg.jp - 2 - -3-. 20kg 60% 2kg 2 3 -4-30 3 15 3-0.05 0.4 NaOH 0.5 20 -5-. 1 1,757g 69% 30 -6- -7- -8- C C H17 18
取扱説明書 ［F-05E］
F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c
1
1.... 1 2.... 1 3.... 2 4.... 3 5.... 4 1)...5 2)...10 3)...14 4)...15 5)...16 6.... 18 7.... 19 8.... 20 1... 25 2... 26 3... 27 1. ( ) 2. - 1 - 3. 1) 2) 3) 6 ( ) 5 4) - 2 - 4. 1) PIO-NET 2) ( 1) (1)
はじめに
[ ] 1 2004 2005 2015 2003 2 1970 200 3 1970 200 1 4 2003 1980 322 2005 JT 1980 5 6 BSEO-157 7 8 9 HACCP 2 HACCPHazard Analysis Critical Control Point System 3 10 4 4 11 2001 1960 12 20032005 PR 500 2004/3
A B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
untitled
1 10 200 2 3 192 B1 PP PP PP PP NG PP 4 CM CM CM CM 20 NG PP PP 5 PP B B1 B1 B1 B B B 6 PP2010 3.5g 350 400 3.5 350 CM 350 PP8 15mmol 600 mmhg 15mmol 600mmHg mmhg PP PP 1 PP PP10 ACE ARB 7 ACE ACE 3.5g
遺産センター2009年報
20 10 20 21 400 20 2218 22 34 22 12 1 .......................................................................................... 4.............................................................................................
2 2 TEL.03-5286-1681 http://www.adic.rise.waseda.ac.jp/adic/index.html FAX FAX03-3255-5115 e-mail : gyoki@sonpo.or.jp TEL.03-5286-1681 http://www.adic.rise.waseda.ac.jp/adic/index.html FAX FAX03-3255-5115
第３章 焼却灰溶融システムの現状、焼却灰溶融スラグのリサイクルの動向・問題点
18 5 23 450 100~150 1300 1998 10 25 1 1 27 1819 60 3 300t 28.8t 2 62 118t16 12.3 16h 24 3 4 120t 9.6t24h 3 4 100t24h 15t24h 3 4 600t24h 500t24h 5 2 300t24h 75t24h 6 8 80 24h 9.6 24h 4 300t24h 52 24 11
(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (
![(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (](/thumbs/49/25497123.jpg "(1) 3 (2) 4 (3) (1) 8 () 8 ()] (2) 11 () () 13 () () (1) 16 () 16 () 16 () 19 (")
ISSN1344221X 1. 2 2. 3 (1) 3 (2) 4 (3)19 7 3. 8 (1) 8 () 8 ()] 10 10 11 (2) 11 () 11 11 12 () 13 () 13 3 4 13 14 14 () 14 14 14 14 4. 16 (1) 16 () 16 () 16 () 19 () 19 () 21 () 22 (2) 36 () 36 () 36 (3)